Michael Cinquegrani, MD
Interventional Cardiology · Milwaukee, WINPI 1164473567
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 30.7% of the total. That places this record below the midpoint for interventional cardiology clinicians in WI, where the typical reported total is $3,713.
Across 21 payments — averaging $28.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$185
- Medtronic$106
- Boston Scientific$102
- Edwards Lifesciences$87
- Heartflow, Inc.$46
- Cardiva Medical, Inc.$37
- plus $37 from 2 others
Across 60 payments — averaging $3086.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$185K
What the payments were for
- Food & beverage$57996%
- Education$224%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 5 | $185 |
| Medtronic | 3 | $106 |
| Boston Scientific | 4 | $102 |
| Edwards Lifesciences | 3 | $87 |
| Heartflow, Inc. | 2 | $46 |
| Cardiva Medical, Inc. | 2 | $37 |
| Merck | 1 | $22 |
| Abiomed | 1 | $16 |
How this compares
$601 in reported general payments places this provider in the 20th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 166 | $194,467 |
| EntrestoSacubitril/Valsartan | 61 | $102,432 |
| Repatha SureclickEvolocumab | 77 | $81,686 |
| JardianceEmpagliflozin | 50 | $56,742 |
| XareltoRivaroxaban | 39 | $38,716 |
| FarxigaDapagliflozin Propanediol | 25 | $31,554 |
| Praluent PenAlirocumab | 27 | $29,509 |
| Metoprolol Succinate | 444 | $8,312 |
| Atorvastatin Calcium | 400 | $3,816 |
| Bumetanide | 53 | $2,413 |
| Ezetimibe | 83 | $2,213 |
| ClopidogrelClopidogrel Bisulfate | 159 | $1,925 |
| Ranolazine ErRanolazine | 13 | $1,826 |
| Losartan Potassium | 193 | $1,781 |
| Rosuvastatin Calcium | 110 | $1,541 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Milwaukee
- Michael SalingerMilwaukee$216K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Iyad AzzamMilwaukee$60K
- Montoya TaylorMilwaukee$48K
- Mina IskanderMilwaukee$41K
- Anna LarosaMilwaukee$38K
- Louie KostopoulosMilwaukee$26K
- Daniel JohnsrudMilwaukee$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.